Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

1

May associate with myocarditis (PMID 30790071)

Last update : 26/02/2019
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Internal medicine (Tokyo, Japan) 2018 Aug 01;57;2217-2221 2018 Aug 01
Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment.
Journal for immunotherapy of cancer 2017 Jul 18;5;54 2017 Jul 18
[Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
Revue de pneumologie clinique 2017 Dec;73;326-330 2017 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies